Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Avenue Therapeutics reports corporate and pipeline developments as a specialty pharmaceutical company focused on therapies for rare and neurologic diseases. Its news covers licensing activity for ATX-04, a selective β2-adrenergic agonist in development for Pompe disease, and clinical-development updates for AJ201 in spinal and bulbar muscular atrophy, also known as Kennedy's disease.
Company updates also include financial results, financing and warrant activity, listing-status matters, investor-conference participation, and the completed sale of majority-owned subsidiary Baergic Bio, including rights to BAER-101. These announcements frame Avenue's portfolio around rare neuromuscular, neurologic, and related therapeutic areas.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.